Targets › APOB
4 programs from 4 companies in 8 trials: 4 Phase 3, 2 Phase 1, 2 Phase 2; Metabolic and endocrine, Neurology, Infectious disease; next expected readout Nov 2026.
Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. (UniProt, P04114)
Open in Phaseline: the race on APOB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vir Biotechnology | Elebsiran Apolipoprotein B (APOB) antisense oligonucleotide inhibitor | APOB | Phase 3 | Viral Hepatitis | Nov 2026 |
| Beijing Suncadia Pharmaceuticals | SHR-1918 APOB mRNA antisense oligonucleotide | APOB | Phase 3 | Hypertriglyceridemia; Hyperlipidemia; Hypercholesterolemia | Mar 2027 |
| Arrowhead Pharmaceuticals | ARO-DIMERPA Antisense oligonucleotide (ASO) targeting apolipoprotein B mRNA | APOB | Phase 1 | Hyperlipidemia; Mixed | Jul 2027 |
| Alnylam Pharmaceuticals | ALN-5288 apolipoprotein B (APOB) mRNA silencing agent | APOB | Phase 1 | Alzheimer's Disease | Mar 2030 |
Viral Hepatitis (3) Alzheimer's Disease (1) Hypertriglyceridemia (1) Hyperlipidemia (1) Hypercholesterolemia (1) Hyperlipidemia; Mixed (1)
small molecule (3), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.